drugset / Trial / NCT07415031
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NaParallel-groupOpen-labelTreatment
Summary
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Timeline
- Start
- 2026-05-06
- Primary completion
- 2028-02-16
- Completion
- 2028-02-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | — | — |
| Background | Cetuximab | Monoclonal antibody | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |
| Background | Pemetrexed | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |